Skip to main contentSkip to navigation
Sirius Investors

VIRP.PA Stock: Virbac S.A. Stock Price, Analysis & Insights

Get live VIRP.PA stock price $348.00, comprehensive Virbac S.A. stock analysis, charts, news, and expert forecast. Real-time VIRP.PA stock data and investment insights.

348.00
1.61%Today
VIRP.PAVirbac S.A. • Euronext Paris • Healthcare
Market Cap
2.92B
Volume
4.60K
52W High
389.50
52W Low
296.00

Loading chart data...

Investment Score

Annual (latest period)
Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Founded in 1968 and based in Carros, France, Virbac S.A. is a prominent developer and distributor of a wide array of animal health products and services. The company's global operations extend across France, Europe, Latin America, North America, Asia...

Company Information

CEO
Habib Ramdani
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
6365

Contact Information

Address
13e rue LID - BP 27
Country
FR

Investment Analysis & Business Insights

Healthcare
Drug Manufacturers - General

Investment Highlights

Strong presence in the Healthcare sector with established market position

Valuation metrics suggest potential value opportunity (P/E: 19.3)

Lower volatility stock (Beta: 0.76) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Virbac S.A. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Virbac S.A.
  • Investors should consider how Virbac S.A. fits within their overall portfolio allocation

Market Cap

2.92B

P/E Ratio (TTM)

19.31

Beta

0.76

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

43/100 ⭐⭐⭐

Overall
-1.0%
NYSE
-1.6%
NASDAQ
-0.4%
Sector1D1W1MP/EScore
Financial Services+0.3%+1.3%+1.9%19.8
83/100⭐⭐⭐⭐⭐
Technology+0.8%+1.1%+3.0%52.0
76/100⭐⭐⭐⭐⭐
Basic Materials+0.8%+0.3%+1.9%27.9
69/100⭐⭐⭐⭐
Industrials-0.3%-0.9%+2.7%43.0
64/100⭐⭐⭐⭐
Communication Services-0.8%-1.3%+0.4%21.9
48/100⭐⭐⭐
Consumer Defensive+0.6%+1.6%-2.5%31.2
44/100⭐⭐⭐
Healthcare-1.0%-2.0%+1.5%30.5
43/100⭐⭐⭐
Real Estate+0.5%-1.1%-0.0%50.0
33/100⭐⭐
Energy+0.5%-3.6%-0.0%35.9
31/100⭐⭐
Utilities+2.0%-1.3%-5.1%26.1
31/100⭐⭐
Consumer Cyclical-0.3%+0.3%-0.2%55.8
28/100⭐⭐

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-06-13.